Ulodesine

Cat. No.: HY-19480

CAS No.: 548486-59-5

Molecular Formula: $C_{12}H_{16}N_4O_3$

Molecular Weight: 264.28

Target: Endogenous Metabolite

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 25 mg/mL (94.60 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.7839 mL	18.9193 mL	37.8387 mL
	5 mM	0.7568 mL	3.7839 mL	7.5677 mL
	10 mM	0.3784 mL	1.8919 mL	3.7839 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1 mg/mL (3.78 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1 mg/mL (3.78 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1 mg/mL (3.78 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Ulodesine is a purine nucleoside phosphorylase (PNP) inhibitor. Ulodesine inhibits PNP with IC_{50} value of 2.293 nM/L. Ulodesine can be used for the research of hyporucicemia[1][2].

In Vivo

Ulodesine (i.v.) potently inhibits PNP with IC_{50} value of 2.293 nM/L[1].

Ulodesine (i.v.) eliminates uric acid accumulations in blood of the mouse model[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Xujuan YANG, et al. Establishment of a novel hyperuricemiaanimal model using mice and assessment ofhyporuricemia action of PNP inhibitor Ulodesine.

[2]. Cesar Diaz-Torné, et al. New medications in development for the treatment of hyperuricemia of gout. Curr Opin Rheumatol. 2015 Mar;27(2):164-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA